SEC Form 8-K Summary
Company: EUDA Health Holdings Limited
Reporting period: Current report for events beginning May 22, 2023; signed May 24, 2023. The filing reports board and committee changes under Item 5.02.
Business Context and Governance Changes
- Following the previously disclosed removals of David Capes and Leonard Chee Hyong Chia from the Board, the Board unanimously appointed Ajay Kumar Rajpal and Dr. Kong-Yew Wong as Class I directors to fill the vacancies.
- The Board, as described in the filing, comprises CEO Dr. Kelvin Chen and independent directors Eric Lew and Alfred Lim, together with the newly appointed directors.
- Eric Lew remains Chairman of the Board.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics. It also does not provide financial guidance or an outlook.
Material Changes and Committee Composition
- Ajay Kumar Rajpal was appointed Chairman of the Audit Committee and a member of the Corporate Governance and Nominating Committee and Compensation Committee.
- Dr. Kong-Yew Wong was appointed a member of the Audit Committee, Corporate Governance and Nominating Committee, and Compensation Committee.
- The Audit Committee consists of Ajay Kumar Rajpal, Eric Lew, Alfred Lim, and Kong-Yew Wong, with Mr. Rajpal as Chairman.
- The Corporate Governance and Nominating Committee consists of Alfred Lim, Eric Lew, Ajay Kumar Rajpal, and Kong-Yew Wong, with Mr. Lim as Chairman.
- The Compensation Committee consists of Eric Lew, Alfred Lim, Ajay Kumar Rajpal, and Kong-Yew Wong, with Mr. Lew as Chairman.
Compensation, Outlook, and Risks
- Mr. Rajpal and Dr. Wong will serve until shareholder reelection or earlier removal or resignation.
- Neither new director will receive compensation for board service; the Company will reimburse reasonable service-related expenses.
- The Board determined that both appointees are independent under applicable Nasdaq requirements. Mr. Rajpal was also determined to satisfy Rule 10A-3 requirements and qualify as an audit committee financial expert.
- The filing reports no specific contingencies, unusual financial items, business risks, or management guidance.
Key Facts for Investors to Verify
- Confirm the effective dates and shareholder reelection status of the two Class I director appointments.
- Review subsequent filings for any further changes to board composition, committee membership, or Nasdaq compliance.
- Verify whether the directors’ expense reimbursements or other related-party arrangements are disclosed in later filings.
- Consult the Company’s latest periodic report for financial performance, liquidity, debt, and risk information not included in this 8-K.